Maria Inasu
Researcher, PhD
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
Author
Summary, in English
27-hydroxycholesterol (27HC), synthesized from cholesterol by the enzyme CYP27A1, differentially impacts estrogen receptor positive (ER+) breast cancer (BC) cell growth depending on estrogen levels. This study examined the association between CYP27A1 expression and prognosis in a cohort of 193 premenopausal patients with lymph node-negative primary BC with limited exposure to adjuvant systemic cancer treatments. In multivariable analyses among patients with ER+ tumors, high CYP27A1 protein and mRNA expressions were associated with four- and eight-fold reductions in the incidence of distant recurrence-free survival events: HRadj = 0.26, 95% CI = 0.07–0.93 and HRadj = 0.13, 95% CI = 0.03–0.60, respectively. In vitro studies revealed that 27HC treatment potently inhibited ER+ BC cell proliferation under lipid-depleted conditions regardless of estradiol levels, transcriptionally mediated through the downregulation of ER signaling with a concomitant upregulation of cholesterol export. Importantly, if validated, these results may have implications for adjuvant treatment decisions in premenopausal patients, especially when de-escalation of therapy is being considered.
Department/s
- Breast cancer prevention & intervention
- LUCC: Lund University Cancer Centre
- Personalized Breast Cancer Treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer
- Breast cancer treatment
Publishing year
2021-12-01
Language
English
Publication/Series
npj Breast Cancer
Volume
7
Issue
1
Document type
Journal article
Publisher
Nature Publishing Group
Topic
- Cancer and Oncology
Status
Published
Research group
- Breast cancer prevention & intervention
- Personalized Breast Cancer Treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer
ISBN/ISSN/Other
- ISSN: 2374-4677